In addition, breast cancer cells treated with 5-aza-2′-deoxycytidine (5-Aza-dc), an established DNA methylation inhibitor [31], reduced the methylation level of the E2F1 binding site (Fig. 3G), which, in turn, restored the E2F1 binding on the ESRP1 promoter (Fig. 3H). Here, E2F1 is linked to breast cancer.